COMPANIES

01 AB-BIOTICS BOOTH 3237-15

Probiotics and other nutraceuticals for pharma and food sectors, including AB-FORTIS (cognitive development of children) AB-LIFE (improvement of cardiovascular health) and AB-I3.1 (IBD/IBS). Pharmacogenetic analyses including Neurofarmagen, a DNA chip which identifies the patient's predisposition to the drugs most used in depression, schizophrenia, bipolar disorders or epilepsy. Discovering of new drugs based on Membrane Lipid Therapy.

Contact: Anna Arna uarnau@ab-biotics.com • www.ab-biotics.com

02 AB-THERAPEUTICS BOOTH 3237

AB-Therapeutics is a pharma-biotech company developing a new therapeutic approach for lung and pancreatic cancer: Membrane Lipid Therapy, with significant advantages over chemotherapy: low toxicity and oral administration. The first candidate ABTL0812 reduces tumor growth by 70%, with growth arrest in 10% tumors. It will start clinical trials in 1Q12. Develops proprietary compounds up to clinical proof of concept, to out-license them.

Contact: Carles Domènech contact@ab-therapeutics.com • www.ab-therapeutics.com

03 ADVANCELL BOOTH 3237-22

Advancell is an innovative biopharmaceutical company that addresses patients' unmet medical needs and well-being by developing value-added products. Building a portfolio of high value pharmaceutical products based on its nanomedicine technology and from in-licensing of promising pre-clinical candidates. Focused on indications and therapeutic areas with unmet medical need in oncology, dermatology and CNS.

Contact: Kenneth Weissmah pilar.h@advancell.net • www.advancell.net

04 ANAXOMICS BIOTECH BOOTH 3237-06

We provide Mechanism of Action, Predictive Safety and Drug Reprofiling advanced services for biopharma worldwide. Anaxomics validated and proprietary technology and databases alow biopharma to maximize the value of pipeline by (1) Fully understanding the MoA, (2) Evaluating NCE safety for in- and out-licensing, (3) Discovering new indications for existing drugs, and (4) maximizing value in investing rounds.

Contact: Vesna Radovanovic vesna@anaxomics.com • www.anaxomics.com

05 AROMICS BOOTH 3237-10

AROMICS is a preclinical development biotech company that applies functional genomic and proteomics to drug discovery and development processes (from target identification and validation, to proof of concept studies ultimately leading to IND stage). THe company is also developing its own products mainly focused on novel therapeutics and diagnostic for relevant diseases.

Contact: Carme Plasencia carme.plasencia@aromics.es • www.aromics.es

06 BAKER & MCKENZIE BOOTH 3237

The most established international law firm in Spain and a market leader in the local community. Our 200 lawyers help protect inbound and outbound investment on all legal fronts. We have broad experience and knowledge in a wide range of key market sectors, pioneering projects that help drive meaningful development and legal reform in Spain's business world. Specially in the biotecnologies and farmatheutical industry.

Contact: Marcel Molins marcel.molins@bakermckenzie.com • www.bakermckenzie.com

07 BCN PEPTIDES BOOTH 3237-11

BCN Peptides is focussed on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications. We manufacture from the R&D, through batches for the Clinical Trials, up to Bulk Commercial Quantities. Moreover we have been authorised (March 2010) to work as Pharmaceutical Laboratory for the analysis of pharmaceutical final product.

Contact: Jordi Piro jpiro@bcnpeptides.com • www.bcnpeptides.com

08 BIOEMPRÈN BOOTH 3237

Bioemprèn is a new company founded in March 2010 that would like to be a platform for the promotion, endorsement, validation, appraisal, organization, management and assessment of business projects and initiatives in the biotechnology sector. It has a valuable knowledge of the early stage of biopharmaceutical companies and experience in business development, clinical trials, CMC development of biologic products and in the regulatory process.

Contact: Jaume Amat jamat@bioempren.com • www.bioempren.com

09 BIONURE BOOTH 3237-16

New drugs for the MS (Multiple Sclerosis) treatment, for neurodegenerative diseases (parkinson, Alzehimer,…). Glaucoma (ophthalmology)… New tools for the diagnosis of neurodegenerative.

Contact: Mar Masso info@bionure.com • www.bionure.com

10 CAIXA CAPITAL RISC BOOTH 3237

Caixa Capital Risc is "la Caixa" ´ venture capital company that invests in newly created Spanish companies led by experienced and committed teams and with a high growth Caixa Capital Risc is "la Caixa"´ venture capital company that invests in newly created Spanish companies led by experienced and committed teams and with a high growth potential.

Contact: Jose Antonio Mesa jmesa@caixacapitalrisc.es • www.caixacapitalrisc.es

11 DR HEATLHCARE BOOTH 3237-20

DR HEALTHCARE is a laboratory specialized in biofunctionalism. Its current activity focuses on researching, developing and innovating new non-pharmacological, alternative and co-adjuvant products which aim to relieve pain and correct physical disorders.
Research at physiological level in molecular biology.
Biomedical research on metabolic diseases, among others.

Contact: Juanjo Duelo Riu info@dr-healthcare.com • www.dr-healthcare.com

12 ERA BIOTECH BOOTH 3237-08

ERA Biotech is a dynamic and innovative company offering technologies for the development and enhancement of recombinant protein and peptide products for health, veterinary, feed and energy applications.
Our technologies deliver production and formulation solutions for high-value protein products in a wide range of eukaryotic expression hosts and applications.

Contact: François Devesa info@eraiotech.com • www.erabiotech.com

13 GP PHARM BOOTH 3237-02

GP Pharm, is a Spanish biopharmaceutical company focused on research, development, manufacturing and marketing of products for injection within Urology and Oncology fields, based in proprietary Drug Delivery Systems: microspheres and liposomes.

Contact: Patricia Ferriot pferriot@gp-pharm.com • www.gp-pharm.com

14 GRIFOLS ENGINEERING BOOTH 3237-01

Grifols Engineering is a company specialized in biotech and sterile manufacturing processes. Grifols Engineering offers consultancy and engineering services and also machinery development for the biotech industry (Ultrafiltration units, Filtration Skids, fermentors, CIP's, etc...) We have the know-how to design projects and specific machinery which comply with the European health authorities and the US FDA.

Contact: Oriol Argemi oriol.argemi@grifols.com • www.grifolsengineering.com

15 HEXASCREEN BOOTH 3237-03

Focused on cellular screening in biotechnology, our first product is a system composed of six minibioreactors for measuring and monitoring the main bioprocess parameters of cell growth and metabolism in mammalian cell culture. The HexaBatch is optimum for carrying out cell screening, cell characterisation, cell adaptation, optimisation of culture media and pharmacological tests.

Contact: Javier Amayra jamayra@hexascreen.com • www.hexascreen.com

16 IMMUNOVATIVE DEVELOPMENTS BOOTH 3341-10

ImmunNovative Developments is a technological platform based in the development of new biological drugs for the treatment, prevention and diagnosis of sepsis and other immune-based diseases.

Contact: Josep Lluís Falcó jlfalco@immunnovative.com • www.immunnovative.com

17 INTELLIGENT PHARMA BOOTH 3237-05

Intelligent Pharma is a biotechnology company dedicated to developing, commercializing and applying new computational technologies for drug discovery. We carry out customized computational chemistry projects using cutting-edge technologies which allow to reprofile drugs, identify new active compounds, determine mechanism of action, improve a hit to lead with computer aid or predict ADME/Tox properties.

Contact: Anna Serra aserra@intelligentpharma.com • www.intelligentpharma.com

18 JANUS DEVELOPMENTS BOOTH 3341-04

Specialized in the management of transitional stages of biomedical projects with the mission of transforming knowledge into economic value. JANUS has acquired licensing patent rights over 11 technologies for their early stage development and has worked with various hospitals, public research centers, and private foundations and companies to define development plans of concept testing.

Contact: Natalia Ferrer nferrer@janusdevelopments.com • www.janusdevelopments.com

19 KIMbcn BOOTH 3237

KIMbcn´s mission is to improve the businesses' competitiveness and technological progress of enperprises by offering them specialized services and executing projects related to innovation and transfer of technology and knowledge.

Contact: Martí Dalmasses mdalmases@kimglobal.com • www.kimbcn.org

20 KYMOS PHARMA SERVICES BOOTH 3237-19

Kymos is a CRO providing services in pharmaceutical, biotech and fine chemical industries of i) bioanalysis for preclinical and clinical studies, ii) analytical development and quality control for ingredients and finished products, iii) pharmaceutical formulation and process development in a QbD environment using PAT methodology and NIR. We have direct presence in Spain, Portugal and Italy, as well as we have costumers from other countries.

Contact: Joan Puig de Dou jpuig@kymos.es • www.kymos.es

21 LABORATORIOS RUBIÓ BOOTH 3237-17

We commercialize products addressed to patients suffering from low prevalence diseases. We export to 42 countries and are also active in in-licensing for our domestic portfolio. Focused on areas such as CNS, rheumatology and nephrology. For specific diseases, we provide products for diagnostic, prevention and treatment. Currently, we commercialize more that 30 products such as Rubifen®, Dolquine® and Resincalcio®

Contact: Sonia Barrón sonia.barron@laboratoriosrubio.com • www.laboratoriosrubio.com

22 LIPOTEC BOOTH 3237

Quality research, innovation and scientific rigor are Lipotec's core values. These priorities together with the continual updating of the company's know-how platforms, Molecular Cosmetics and Delivery Systems, enable us to develop an integral approach to fulfill overall beauty demands yet contribute to the sustainable success of our partners.

Contact: Ramon Salsas commercial@lipotec.com • www.lipotec.com

23 LYKERA BIOTECH BOOTH 3237-21

Lykera Biotech is developing innovative drugs for the treatment of cancer by targeting tumour cells, tumor stromal compartment and tumour angiogenesis. Lykera's LK-1 is a first-in-class monoclonal antibody whose target participates in the three tumour compartments. LK-1 has in vivo proof-of-principle and is now under the humanization process. Next steps include regulatory preclinical phases.

Contact: Francesc Mitjans lykera@lykerabiotech.com • www.lykerabiotech.com

24 NEUROTEC PHARMA BOOTH 3237-07

Our activity is focused on developing new treatments for central nervous system diseases. Currently, our interest is on developing an oral treatment (NT-KO-003) for Multiple Sclerosis based on reprofiling of a drug with a novel mechanism of action centered on inhibition of microglial reactivity. In January 2011, Neurotec has requested a Clinical Trial Application for the execution of a Clinical Phase IIa that is going to begin in April 2011.

Contact: Marco Pugliese marcopugliese@neurotec-pharma.com • www.neurotec-pharma.com

25 OMNIA MOLECULAR BOOTH 3237-04

Omnia develops proprietary antibiotics targeted at difficult-to-treat hospital infections with a proprietary platform to rapidly design small chemical structures against a well characterized molecular target. Lead compounds are optimized and proven effective in animal models before being presented as candidates for co-development with pharma industry partners.

Contact: Ralph Klingmann landreu@omniamol.com • www.omniamol.com

26 ORYZON BOOTH 3341-06

1 small molecules LSD1i program in cancer. 2 LSD1i/MAO-B programs in CNS. Early diagnostics gene expression test for Endometrial cancer. Functional Genomic Platform: biomarker/target discovery programs, microarray designs, Toxicogenomics/Pharmacogenetics studies for the Industry. NMR and X-Ray Crystallography combined with medicinal chemistry and computational methods for novel chemical series.

Contact: Emili Torrell etorrell@oryzon.com • www.oryzon.com

27 PALAU PHARMA BOOTH 3237-09

We are seeking innovative drug discovery alliances to jointly design and develop novel small molecule drugs, pursuing partnerships in order to broaden and diversify our development pipeline through the in-licensing of new chemical entities or new formulation projects, establishing partnerships with leading biotec and pharma companies for the late stage development and commercialization of our projects beyond Phase II clinical trials.

Contact: Heidi Sisniega hsisniega@palaupharma.com • www.palaupharma.com

28 REIG JOFRÉ GROUP BOOTH 3237-12

Leader in manufacturing and out-licensing worldwide, of dossiers of generic products and galenic modifications. More than 165 laboratories around the world guarantee the quality of our services. RJ-Biotech Services offers a global biopharmaceutical development from research to commercialization. We have a pilot plant certified with GMP for investigational medicinal products.

Contact: Isabel Amat isabel.amat@reigjofre.com • www.reigjofre.com

29 RPS RESEARCH IBERICA BOOTH 3237

RPS, a next generation CRO, provides comprehensive global Phase 1-4 clinical development solutions to the pharmaceutical, biotechnology and medical device industries. RPS is uniquely positioned to offer our Clients both integrated and full service global outsourcing solutions. These solutions are powered by highly experienced and seasoned study teams providing innovative, cost-effective and high quality services.

Contact: Jose Manuel Mas Benavente research.spain@rpsweb.com • www.rpsweb.com

30 SALUPHARMA BIOSIMILARS BOOTH 3237

Biosimilars are high-quality replicas of existing pharmaceuticals (gone off patent) developed under the European Medicines Agency (EMA) standards, and that are proven to be as efficient and safe as their innovator counterparts. We are looking for partners of acknowledged solvency who are interested in the development and/or marketing of EMA-approved biosimilars. We also provide consultancy services to companies from less regulated areas wishing to launch in Europe.

Contact: Ana Aldea salupharma@salupharma.com • www.salupharma.com

31 SALUTIS INTERNATIONAL BOOTH 3341-08

Salutis International is a full-service CRO with headquarters in Barcelona, Spain. We design, set up and run clinical trials from phase I-IV, both on the Iberian Peninsula and across the globe with our associated partners. Salutis specialises in biotechs and helps them taking their compounds from pre-clinic to phase II. We offer reliable quality, delivered in an efficient and cost effective way.

Contact: Eva Hurst eva.hurst@salutis-international.com • www.salutis-international.com

32 SALVAT BOOTH 3237-18

Spanish pharmaceutical group, devoted to the research, manufacture and marketing of pharmaceuticals. Commercial area of interest include gastroenterology, ENT, urology, pediatrics and ophthalmology. Research areas include ENT, urology, ophthalmology, dermatology, regenerative and predictve medicine. Our products are marketed worlwide, mainly by means of licensing-out agreements. We are looking for out-licensing and in-licensing opportunities.

Contact: Cristina Viayna cviayna@salvatbiotech.com • www.salvatbiotech.com

33 TELSTAR BOOTH 3237

Through our Telstar Life Science Solutions division we provide equipment solutions for the pharmaceutical, medical-hospital, biotech, laboratories and related industries. With over 45 years of experience and an international presence in more than 100 countries, we have a broad range of references in the major companies and are established as a worldwide leader in the field. Telstar has a trained, highly qualified and expert sales force to provide the best advice and service to the customer base.

Contact: Núria Batet telstar@telstar.eu • www.telstar.eu

34 THROMBOTARGETS EUROPE BOOTH 3237-13

TT-173: topical haemostat based in vesiculated recombinant human Tissue Factor (fast hemostasis, stable, easy to use, useful in healthy subjects and in all kind of caogulopathies). BIOPLATFORMSCRREN™ : HTS of coagulation/fibrinolysis pathway

Contact: Ignasi Miquel ignasimiquel@thrombotargets.com • www.thrombotargets.com

35 TRIFERMED GROUP BOOTH 3237-24

The first Contract Business Development Organization with the aim of supporting International Business Development activities of BioHealth companies. We provide services in the areas of International Partnering, Market Scout, Market Understanding, Advise on Business Strategy and Knowledge Management. Based in Barcelona, we also have offices in Mexico and Brazil, and are active in Europe, Canada, Latin America, and Israel.

Contact: Esther Bonet ebonet@trifermedgroup.com • www.trifermedgroup.com

36 VCN BIOSCIENCES BOOTH 3237-14

Develops new therapies for tumors that lack effective treatment. We use the oncolytic adenovirus platform to design highly efficient agents that replicate and self-amplify exclusively in tumor cells. VCN viruses selectivity allows their systemic administration and contrary to chemotherapy, its effective dose increases with time. These properties highlight VCN candidates as promising alternatives for tumors such as pancreatic and head & neck carcinomas.

Contact: Manel Cascalló mcascallo@vcnbiosciences.com • www.vcnbiosciences.com

37 YSIOS CAPITAL PARTNERS BOOTH 3237

Ysios Capital Partners is one of the first independent venture capital firms in Spain providing private equity financing to early and mid-stage human healthcare and biotechnology companies with special focus on pharmaceuticals, diagnostics and medical devices. Ysios launched its first fund of 69M €, Ysios BioFund I, in 2008. Ysios has four portfolio companies and one successful divestment.

Contact: Raul Martín www.ysioscapital.com • ysios@ysioscapital.com

INSTITUTIONS

01 BIOCAT BOOTH 3237

Biocat is the organization that dynamises all the agents and initiatives involved in biotechnology, biomedicine and medical technology sector in Catalonia, shaping an environment with a strong research system, active in technology transfer, and with an industrial tissue capable of becoming the economic driver of Catalonia and contributing to society's quality of life. It is fostered by the Government of Catalonia and the Barcelona City Council.

Contact: Adela Farré info@biocat.cat • www.biocat.cat

02 ACC1Ó BOOTH 3237

Is the economic development agency of the government of Catalonia, Spain. ACC1O is headquartered in Barcelona and has 35 offices around the world. With a focus on innovation and internationalization, offers practical assistance to Catalan companies expanding in international markets and helps foreign companies grow their business in Catalonia by providing advice and practical support.

Contact: Clara Barreneche newyork@acc1o.com • www.acc10.com

03 UAB BOOTH 3237

UAB IP Office is in charge of: 1. Detecting technologies to become interesting products for the market. 2. Evaluating projects and protecting these results by patenting them. 3. Looking for industrial partners to commercialize products originated from technology. 4. Licensing patents, helping to obtain funds to develop the proof of concept, etc. 5. Connecting the university research with the market in order to commercialize products.

Contact: Xavier S. Vallvé patents@uab.ca • www.uab.es

04 BARCELONA BIOTECH BOOTH 3237

Biotechnology is strategic for the economic growth of Barcelona. Barcelona Biotech is the result of the joint venture of the Barcelona City Council and Biocat to consolidate this location as one of the leading poles of competitiveness in Europe. It will be focused on strengthening this relevance and attracting investment and events to Barcelona.

Contact: Jordi Sacristán xtestar@bcn.cat • www.bcn.cat/barcelonabusiness

05 IRB BARCELONA BOOTH 3237

The Institute for Research in Biomedicine is a non-profit research organization devoted to basic biomedical research in Oncology, Structural and Computational Biology, Molecular Medicine, Cell and Developmental Biology and Chemistry.

Contact: Cristina Horcajada innovation@irbbarcelona.org • www.irbbarcelona.org

06 PARC CIENTÍFIC DE BARCELONA BOOTH 3237

The Barcelona Science Park goals are: To potentiate quality research with the support of a wide range of technologies, to facilitate the exchange between university and business, to promote the creation of new companies and institutions and to further the science-society dialogue and encourage careers in science. The park is home to 3 research institutes, 75 companies, an incubator for biotechnology companies and a wide range of technology support facilities.

Contact: Jesús Purroy jpurroy@pcb.ub.cat • www.pcb.ub.cat

07 CREB-UPC BOOTH 3237

At present, 80 professionals are employed at the Centre, of which 42 are doctors in engineering, physics and computers and 38 have bachelor's degrees. The CREB is estructured in the following areas: Biomaterials, Biomechanics and Tissue Engineering Division, Biomedical Signals and Systems Division, Roboticsand Vision Division, Instrumentation and Bioengineering Division, Dosimetry and Ionizing Radiation Division and Computer Graphics Division.

Contact: Manel González manel.gonzalez@upc.edu • www.creb.upc.es

08 BIONANOMED CATALUNYA BOOTH 3237

Nanobiomedicine is one of the strong points of research in Catalonia and the BioNanoMed Catalonia alliance has been created to extract all its potential. It has also been designed to encourage synergy between groups, centres, hospitals and companies carrying out research in nanotechnology applied to health and biotechnology in Catalonia. The aim is to create new research and business opportunities and increase its international recognition.

Contact: Marta Príncep mprincep@biocat.cat • www.bionanomedcat.org

09 ICN BOOTH 3237

The ICN is a Nanoscience & Nanotechnology Research Center. Main lines: nanobiomedicine, nanostructured materials, nanoparticles, magnetism, spintronics, imaging and manipulation of molecules, theory of surfaces, interaction of biomaterials with inorganic matter. It participates into NANOARACAT, collaboration Frame Program between Aragon and Catalan governments for promotion of the N&N benefits.

Contact: Jordi Reverter jordi.reverter@icn.cat • www.icn.cat

10 CRG BOOTH 3237

The CRG is a pioneering centre in Spain, based on a non-bureaucratic organisation research model, devoted to promoting basic research about fundamental life science issues, with a focus on genomics, proteomics and biomedical research, attracting and producing top scientists at all levels. The CRG is in the unique position of being a top-level institute not belonging to a large corporation.

Contact: Xavier Rúbies xavier.rubies@crg.eu • www.crg.eu

11 FCRB BOOTH 3237

The Clinic Foundation for Biomedical Research was created 10 1989 in Barcelona. Its mission is to promote, support and manage biomedical research and innovation, focusing on the areas of expertise of the Clinic Hospital / University of Barcelona, Oncology, Liver and GI diseases, Cardiovascular, Diabetes, CNS, Dermatology, Respiratory and Orphan and Neglected Diseases.

Contact: Albert Zamora azamora@clinic.ub.es • www.fundacioclinic.org

12 LEITAT BOOTH 3237

LEITAT Technological Center´s objective is to provide technological solutions to the demands of enterprises, public institutions, government agencies, universities and other research institutes while committed to encourage the management of R & D as a process for sustainable growth in the competitiveness of companies.

Contact: Anna Surribas asurribas@leitat.org • www.leitat.org

13 ONCOCAT BOOTH 3237

Oncology is the medical specialty of greatest importance in Catalonia from the healthcare point of view, as is basic, translational and clinical research involving organisations from throughout the whole value chain. The network has been created to favour the co-ordination of hospitals, research institutes and companies working in this area, to encourage synergy between them, emergence of common projects, and their international projection.

Contact: Marta Príncep mprincep@biocat.cat • www.oncocat.org

14 PARC DE L'ALBA BOOTH 3237

This project is creating an international knowledge hub in the heart of the Barcelona metropolitan region, that can bring together 40,000 jobs linked to added value activities. This strategic area features one of the most advanced research facilities in Europe –the Alba synchrotron –, a first-rate university campus – the Universitat Autònoma de Barcelona–, and an exceptional concentration of knowledge infrastructures as well as industrial and business parks.

Contact: Valentí Llagostera vllagostera@parcdelalba.cat • www.parcdelalba.cat

15 GRIB (IMIM-UPF) BOOTH 3237

We carry out fundamental research and technological developments on the application of advanced information technologies and computational methods in the health and life sciences. GRIB has a wide experience in the participation and coordination of research projects funded by the European Commission and other agencies. GRIB has a long tradition of collaboration with the pharma and biotec industry in the framework of R&D projects and also providing services especially in the development of computational methods for drug discovery.

Contact: Melquiades Calzado mcalzado@imim.es • www.grib.imim.es

16 UAB RESEARCH PARK BOOTH 3237

Our aim is to stimulate and improve technology and knowledge transfer activities of its members, to promote entrepreneurship activity and to provide interaction between research and industry. Nowadays, the PRUAB has 25 research centres and institutes who work in these fields: Biomedicine and Biotechnology, Information and Communication technologies, Material sciences, Environment, Animal Health and Food Technology, Human and Social ciences.

Contact: Xavier S. Vallvé parc.recerca@uab.cat • www.parc.uab.cat

17 UPC BOOTH 3237

Universitat Politècnica de Catalunya-BarcelonaTech is a public institution dedicated to higher education and research specialized in fields of architecture, science and engineering. The UPC has a vision of innovation and talent in a global and highly competitive world. Our university is forward-looking to teach high quality courses evolving and developing sectors, including aeronautics, photonics, supercomputing, bioengineering and energy.

Contact: Elena López elena.lopez-cano@upc.edu • www.upc.edu

		AB-BIOTICS 01	AB-THERAP. 02	ADVANCELL 03	ANAXOMICS 04	AROMICS 05	BAKER McKEN. 06	BCN PEPTIDES 07	BIOEMPRÈN 08	BIONURE 09	CAIXA CAP. RISC 10	DR HEATLHCARE 11	ERA BIOTECH 12	GP PHARM 13	GRIFOLS ENG. 14	HEXASCREEN 15	IMMUNOVATIVE 16	INTELLIGENT PH. 17	JANUS DEV. 18	KIMBCN 19	KYMOS PH. 20	LAB. RUBIÓ 21	LIPOTEC 22	LYKERA BIO. 23	NEUROTEC PH. 24	OMNIA MOLEC. 25	ORYZON 26	PALAU PH. 27	REIG JOFRÉ 28	RPS RES. 29	SALUPHARMA 30	SALUTIS INT. 31	SALVAT 32	TELSTAR 33	THROMBOTAR. 34	TRIFERMED 35	VCN 36	YSIOS 37
SECTOR	HUMAN HEALTH (DIAGNOSTIC - VACCINATIONS)				■	■		■		■		■				■			■		■		■		■			■		■		■		■	■	■			
	HUMAN HEALTH (THERAPEUTIC)	■	■	■	■	■		■		■		■	■	■		■	■		■		■	■		■	■	■	■	■	■	■	■	■	■	■	■	■	■		
	AGROFOOD (AGRICULTURE, LIVESTOCK FARMING, FOOD & FORESTRY)	■			■	■						■																						■					
	ANIMAL HEALTH				■	■		■				■	■			■			■		■													■		■			
	BIOPROCESSES, BIOFUELS, BIOMATERIALS												■		■	■																		■		■			
	AUXILIARY SERVICES	■			■				■										■		■													■					
	ENVIRONMENT																																	■					
	AQUACULTURE																																	■					
	BIO PHARMACEUTICS ENGINEERING CONSULTANCY														■																								
	COMPUTATIONAL SERVICES																	■																					
	VENTURE CAPITAL*/ LAW FIRM**						**				*																												*
	INNOVATION AND TECH TRANSFER CONSULTANCY																			■																			
	COSMETICS																						■															
	BIOSIMILAR MEDICINE																															■						
PRODUCT DEVELOPMENT PHASE — PHARMACEUTICAL DEVELOPMENT	BASIC RESEARCH (RESULT FOR RESEARCH)	■			■	■				■			■	■			■		■		■		■	■				■					■				
	PRECLINICAL (IN VITRO TRIAL)	■	■	■	■	■				■			■	■			■		■		■		■	■	■	■		■			■			■				
	PRECLINICAL (IN VIVO TRIAL)	■		■	■	■				■			■	■			■		■		■		■	■	■	■	■	■				■		■		■		
	CLINICAL PHASE I, II, & III			■	■							■		■			■		■		■	■			■	■		■	■		■	■						
	CLINICAL PHASE IV (IN MARKET)				■							■		■							■	■	■						■		■		■						
DIAGNOSTIC	BASIC RESEARCH (RESULT FOR RESEARCH)	■			■					■							■		■					■											■			
	PILOT PRODUCT	■			■	■													■					■						■		■						
	VALIDATION TRIALS	■			■	■													■									■		■	■	■						
	REQUEST FOR AUTHORISATION	■																	■			■								■		■						
	IN MARKET	■										■							■			■								■		■			■			